{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-134969","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.220171+00:00","generated_at":"2026-05-29T05:12:44.477075+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Spruce Biosciences discontinues tildacerfont CAH program after Phase 2b miss","bullets":["Phase 2b CAHmelia-204 missed primary endpoint: placebo-adjusted GC dose reduction of 0.7mg HCe (p=0.7).","98% compliance; no serious adverse events reported in CAHmelia-204.","Phase 2 CAHptain-205 showed trend of larger A4 reductions at higher BID doses; no drug-related SAEs.","Company discontinuing both trials, winding down tildacerfont investment, and evaluating strategic options."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-134969","json":"https://secwatch.observer/filing/0000950170-24-134969.json","markdown":"https://secwatch.observer/filing/0000950170-24-134969.md","text":"https://secwatch.observer/filing/0000950170-24-134969.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017024134969/0000950170-24-134969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017024134969/sprb-20241210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:12:44.477075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}